Four fold increase in risk of infectious complications after stem cell transplant with oral mucositis than without.
www.mdpi.com/2072-6694/17...

Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress | NEJM Combined treatment with a tyrosine kinase inhibitor and blinatumomab has converted Ph-positive ALL, once the most deadly hematologic cancer, to a disease with long-term survival of 75 to 80%.

www.nejm.org/doi/full/10....

Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure | NEJM Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced (armore...

www.nejm.org/doi/full/10....

Novel strategies to manage CAR-T cell toxicity - Nature Reviews Drug Discovery Treatment with chimeric antigen receptor (CAR)-T cell therapies is associated with important immune-related adverse events. In this Review, the authors discuss the standard-of-care management for...

STOP CAR, ON CAR, OFF CAR, SNIP(er) and VIPER(s) and many other strategies!

www.nature.com/articles/s41...

CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 | NEJM Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case o...

Although very rare, some brakes needed for the CARs
www.nejm.org/doi/full/10....

Bone Marrow Transplant Team Provides Lifesaving Care for German Patient with Rare Brain Cancer - UConn Today As the couple prepares to head back to Germany, they say they will always consider UConn Health their second home

A team that is incredibly passionate and tireless.A leadership that’s phenomenal and visionary. United in a common mission to offer hope and bring smiles.A success story of possibilities and resilience on the anniversary of our new BMT program and honored to lead it!

today.uconn.edu/2024/12/bone...

Secondary malignancies after CAR-T

jamanetwork.com/journals/jam...

Sun. Fog. Dusk. Dawn
Science and research
Dibble dibble dibble dopp
🩸🩸🩸

#ASHaiku #ASH24
@ash-hematology.bsky.social

Greener looks the grass
Soil back to fertile
MRD awaits

#ASHaiku #ASH24

@ash-hematology.bsky.social

Thanks to @ash-hematology.bsky.social for this feed to catch up #ASH24 in one place! No more FOMO for virtual attendees ✋🏽

This poem, entitled 'Needles' is presented in the form of a Christmas tree. These words form the shape of the tree: I wrote a poem in the shape of a Christmas tree but then forgot to water it and only a few days later there And these words are distributed around the base of my poem 'tree' as if they've fallen off it: were words all over the carpet

Today’s poem is called ‘Needles’.

#ASH24 educational Program 2024. Treasure trove of🩸🩸🩸updates

ashpublications.org/hematology/i...

Jobs | UConn Health Nursing Careers If you want to be part of a team where nurses are respected, valued, and encouraged to learn and grow, you want to be a nurse at UConn Healt ...

We are hiring ! Looking for a BMT/cell therapy RN for our growing new BMT program. Check out the link - 'Join Our Team today' and scroll to page two for more details or DM me if anyone is interested.

health.uconn.edu/jobs

Severe aplastic anemia. ASTCT guidelines 2024

www.astctjournal.org/article/S266...

Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia | NEJM Obecabtagene autoleucel (obe-cel) is an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy which uses an intermediate-affinity CAR to reduce toxic effects and improve persis...

Yet another CAR-T success story.
Obe-cel in B-ALL

www.nejm.org/doi/full/10....

An excellent review characterizing the role of imetelstat in lower-risk MDS!

ashpublications.org/blood/articl...

✋🏽 Virtual though

ECOG-ACRIN 4151: MCL pts in CR1 with undetectable MRD6 did not benefit from consolidative auto-HCT. Pts who remain MRD+ after induction may benefit from auto-HCT. LBA #ASH24
ash.confex.com/ash/2024/web...

bsky.app/profile/kisw...

If you're interested in Stem cell transplant and/or Cellular Therapy this is the list #bmtsm #CARTcells #leusm #mmsm #lymsm #MedSky #TcellRx go.bsky.app/7xxh8WW

4-gene prognostic risk classifier (FLT3-ITD, KRAS, NRAS, and TP53) seems to successfully differentiate outcomes among patients with newly diagnosed AML treated with Aza/Ven than ELN 2017/2022

ashpublications.org/blood/articl...

Ph 1 CD7 targeted CAR for R/R AML. Great CR rate (70%) in extensively treated pts. But short DoR without alloSCT. Relapse with CD7 loss

ashpublications.org/blood/articl...

Great review on NLPHL

haematologica.org/article/down...

Intriguing T-follicular helper (TFH) lymphomas

haematologica.org/article/view...

Haven’t experienced that personally but can totally understand!

Yes, agree, that’s been the main issue in solid onc. Hopefully not for too long

Beyond the blood: expanding CAR T cell therapy to solid tumors - Nature Biotechnology Recent clinical trials testing CAR T cells on solid tumors have yielded promising outcomes that can be enhanced with further CAR engineering.

Beyond the blood: expanding CAR-T to solid tumors

www.nature.com/articles/s41...

Acute myelopathy following CAR-T
ashpublications.org/blood/articl...

Thanks @kiswanson.bsky.social for the great starter packs! Would appreciate if I could be added to one

A breakthrough cancer immunotherapy is now taking aim at autoimmune disease CAR-T therapy is generating excitement for lupus, scleroderma, and other conditions as clinical trials expand

Exciting to see #cell therapy #CAR-T making in roads in non-oncology conditions

CAR-T for autoimmune disorders

www.science.org/content/arti...